Menu
Recruiting NCT06995131

Evaluation of Aqueous Humor DEL-1 and IL-17 Levels in Diabetic Cataract Patients

No phase Interventional Diabetic Group (n=30) Non-diabetic Group

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Del 1, IL 17.
Who it may be relevant to
Registry conditions: Diabetic Group (n=30), Non-diabetic Group. Basic parameters: 50 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

By comparing DEL-1 and IL-17 levels in the aqueous humor of diabetic cataract patients with the aqueous humor of non-diabetic patients, we aim to understand the biochemical effects of diabetes-related inflammatory processes in the eye.

Detailed description

Developmental Endothelial Locus-1 (DEL-1) is a molecule related to endothelial cells and is a protein involved in intercellular interactions. It is generally associated with the development and function of endothelial cells lining the inner surface of the vessel. It plays an important role in the regulation of inflammation, the development of vessels and the organization of endothelial cells. It has also been shown to be associated with some types of cancer. It may also be effective in tissue regeneration and healing of injuries.

IL-17 (Interleukin-17) is a group of cytokines that play an important role in the immune system. There are several subtypes of IL-17, the best known and most researched being IL-17A. It regulates the body's immune response to certain infections. It is an important cytokine that initiates and supports the inflammation process. IL-17 plays an important role in the pathogenesis of various autoimmune and inflammatory diseases.

DEL-1 and IL-17 are two different molecules that act on inflammation and immune responses. DEL-1 helps regulate inflammation by protecting vascular health, while IL-17 can accelerate the course of diseases by increasing inflammation.

Diabetes is a systemic disease associated with oxidative stress and chronic inflammation. Retinopathy, cataract and glaucoma diseases develop due to diabetes. DEL-1 is a protein involved in the maintenance of vascular homeostasis and regulation of inflammation. Since diabetic patients have chronic inflammation and microvascular dysfunction, changes in DEL-1 levels may provide important clues to the pathophysiology

Interventions

  • Diagnostic test Del 1
    During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. DEL 1 will be analyzed by ELISA
  • Diagnostic test IL 17
    During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. IL 17 levels will be analyzed by ELISA

Primary outcome measures

  • DEL-1 and IL-17 levels [Time frame: Perioperative]
Secondary outcome measures (3)
  • Correlation between DEL-1 and IL-17 [Time frame: Perioperative]
  • Association of biomarker levels with HbA1c [Time frame: Perioperative]
  • Impact of demographic factors [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Cataract diagnosed and surgery planned
  • Patients without any other ocular pathology other than cataract.
  • Type 2 DM for at least 5 years in the diabetic group

Exclusion criteria

  • Patients with previous intraocular surgery
  • Those with inflammatory eye diseases (e.g. uveitis)
  • Those with autoimmune diseases or systemic inflammatory diseases
  • Those receiving local or systemic steroid therapy
  • Those with severe systemic disease (e.g. advanced renal failure, malignancy)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Crossover
Masking
Single blind
Primary purpose
Screening

Study locations

Turkey (Türkiye) · 1 center
  • Uşak Training and Research Hospital — Uşak

Publications

  • Dogruya S, Sagkan RI. Levels of DEL-1 and IL-17 in the aqueous humor of cataract patients with diabetes without diabetic retinopathy. Int Ophthalmol. 2026 Jun 25;46(1):270. doi: 10.1007/s10792-026-04142-3. PMID 42347979

Identifiers

NCT: NCT06995131 · DEL 1- IL 17

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗